Main public logs
Jump to navigation
Jump to search
Combined display of all available logs of Azupedia. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 10:01, 14 February 2024 Fire talk contribs created page physiological absorption (Q20923) (wbeditentity-create:2|en: physiological absorption, uptake of substances by or in the body, via biological transport or by simple diffusion)
- 10:01, 14 February 2024 Fire talk contribs created page skin absorption (Q20922) (wbeditentity-create:2|en: skin absorption, route through which substances may be received)
- 09:56, 14 February 2024 Fire talk contribs created page Discovery and development of gliflozins/ja (Created page with "グリフロジンの発見と開発")
- 09:56, 14 February 2024 Fire talk contribs created page Translations:Discovery and development of gliflozins/Page display title/ja (Created page with "グリフロジンの発見と開発")
- 09:56, 14 February 2024 Fire talk contribs marked Discovery and development of gliflozins for translation
- 09:56, 14 February 2024 Fire talk contribs limited languages for translatable page Discovery and development of gliflozins to Japanese
- 09:46, 14 February 2024 Fire talk contribs created page Category:Drug discovery (Created page with "{{Commons category}} {{Cat main|Drug discovery}} Category:Clinical research Category:History of pharmacy Category:Life sciences industry Category:Medicinal chemistry Category:Pharmaceutical industry Category:Pharmaceutics Category:Pharmacognosy Category:Pharmacology {{CatAutoTOC}}")
- 09:45, 14 February 2024 Fire talk contribs created page Discovery and development of SGLT-2 inhibitors (Q20921) (wbeditentity-create:2|en: Discovery and development of SGLT-2 inhibitors)
- 09:44, 14 February 2024 Fire talk contribs created page Template:Drug design (Created page with "{{Navbox |name = Drug design |title = Drug design |listclass = hlist |state = autocollapse |group1 = Steps in design |list1 = * Drug discovery * Hit to lead * Drug development ** Preclinical ** Clinical *** Phases |group2 = Case studies of discovery <br /> and development of drug classes |list2 = * Discovery and development of 5α-reductase inhibitors|5α-Reductase inhibito...")
- 09:41, 14 February 2024 Fire talk contribs created page Discovery and development of gliflozins (Created page with "Gliflozins are a class of drugs in the treatment of type 2 diabetes (T2D). They act by inhibiting sodium/glucose cotransporter 2 (SGLT-2), and are therefore also called SGLT-2 inhibitors. The efficacy of the drug is dependent on renal excretion and prevents glucose from going into blood circulation by promoting glucosuria. The mechanism of action is insulin independent. Three drugs have been accepted by the Food and Drug Administration (FDA) in t...")
- 09:31, 14 February 2024 Fire talk contribs created page Template:Sodium-glucose transporter modulators/ja (Created page with "{{Navbox | name = Sodium-glucose transporter modulators/ja | title = Sodium-glucose transporter/ja モジュレーター | state = {{{state<includeonly>|collapsed</includeonly>}}} | listclass = hlist | groupstyle = text-align:center; | group1 = {{abbrlink|SGLT1|Sodium-glucose transporter 1/ja}} | list1 = * '''阻害薬:''' Phloretin/ja * Phlorizin/ja * T-1095/ja * T-1095A/ja | group2 = {{abbrlink|SGLT2|Sodium-gl...")
- 09:22, 14 February 2024 Fire talk contribs created page restlessness (Q20920) (wbeditentity-create:2|en: restlessness, lack of calm, peace, or ease)
- 09:21, 14 February 2024 Fire talk contribs created page psychomotor agitation (Q20919) (wbeditentity-create:2|en: psychomotor agitation, a set of signs and symptoms that stem from mental tension and anxiety; the signs are unintentional and purposeless motions; the symptoms are emotional distress and restlessness)
- 09:17, 14 February 2024 Fire talk contribs created page mania (Q20918) (wbeditentity-create:2|en: mania, state of abnormally elevated or irritable mood, arousal, and/or energy levels)
- 09:18, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/45/ja (Created page with " Category:Anti-diabetic drugs")
- 09:18, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/44/ja (Created page with "{{Oral hypoglycemics/ja}} {{Sodium-glucose transporter modulators/ja}} {{Portal bar | Medicine}}")
- 09:17, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/43/ja (Created page with "==外部リンク== * {{cite web | title=FDA revises label of diabetes drug canagliflozin | website=U.S. Food and Drug Administration | date=15 January 2016 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet }} * {{cite web | title=FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana,...")
- 09:17, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/42/ja (Created page with "SGLT2阻害薬は、NAFLDと2型糖尿病の患者を対象とした臨床試験において、また2型糖尿病でない患者を対象とした臨床試験において、肝機能に対する有益な効果を示している。")
- 09:17, 13 February 2024 Fire talk contribs created page Mallet-Guy's sign (Q20917) (wbeditentity-create:2|en: Mallet-Guy's sign, medical condition)
- 09:16, 13 February 2024 Fire talk contribs created page pancreatitis (Q20916) (wbeditentity-create:2|en: pancreatitis, inflammation of the pancreas)
- 09:11, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/41/ja (Created page with "グリフロジンは、試験管、前臨床試験および臨床試験において、心臓、肝臓、腎臓の保護作用、抗高脂血症作用、抗動脈硬化作用、抗肥満作用、抗腫瘍作用などを示すとされている。 このクラスの多能性作用は、ナトリウム利尿、血液濃縮、レニン-アンジオテンシン-アルドステロン系の不活性化、ケトン体形成...")
- 09:08, 13 February 2024 Fire talk contribs created page pupil symptom (Q20915) (wbeditentity-create:2|en: pupil symptom, symptom)
- 09:07, 13 February 2024 Fire talk contribs created page dilated pupil (Q20914) (wbeditentity-create:2|en: dilated pupil, symptom)
- 09:05, 13 February 2024 Fire talk contribs created page mydriasis (Q20913) (wbeditentity-create:2|en: mydriasis, Increase in size of the pupil's diameter and dilation)
- 09:03, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/40/ja (Created page with "== 研究 == {{Anchor|Research}} SGLT2阻害薬は循環ケトン体濃度を上昇させる。SGLT2阻害薬の心臓保護作用はケトン体濃度の上昇に起因している。")
- 09:02, 13 February 2024 Fire talk contribs created page vision distortion (Q20912) (wbeditentity-create:2|en: vision distortion, symptom)
- 09:01, 13 February 2024 Fire talk contribs created page blurred vision (Q20911) (wbeditentity-create:2|en: blurred vision, symptom, lack of sharpness of vision resulting in the inability to see fine detail)
- 08:59, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/39/ja (Created page with "==歴史== {{Anchor|History}} {{Main/ja|Discovery and development of gliflozins/ja}}")
- 08:59, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/38/ja (Created page with "グリフロジンの開発において、遠位環は芳香環の代わりにチオフェン環を含んでいた。しかし、市販されているグリフロジンの最終的な化学構造には、このチオフェン環は含まれていない。")
- 08:58, 13 February 2024 Fire talk contribs created page giddiness (Q20910) (wbeditentity-create:2|en: giddiness, symptom)
- 08:53, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/37/ja (Created page with "thumb|カナグリフロジン")
- 08:53, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/36/ja (Created page with "例えば、カナグリフロジンの化学構造において、フッ素原子が芳香環に結合している場合、その化合物はより安定し、代謝が低下する。 エンパグリフロジンにはテトラヒドロフラン環があるが、カナグリフロジンやダパグリフロジンにはない。")
- 08:52, 13 February 2024 Fire talk contribs created page hypoactivity (Q20909) (wbeditentity-create:2|en: hypoactivity, inhibition of behavioral or locomotor activity)
- 08:52, 13 February 2024 Fire talk contribs created page hypokinesia (Q20908) (wbeditentity-create:2|en: hypokinesia, movement disorder)
- 08:51, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/35/ja (Created page with "thumb|Dapagliflozin thumb|エンパグリフロジン")
- 08:51, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/34/ja (Created page with "ダパグリフロジンの糖類似体において、β-C系列はα-C系列よりも活性が高いため、阻害活性のためにはβ-配座がC-1であることが重要である。ダパグリフロジンとエンパグリフロジンは、化学構造中に塩素（Cl）原子を含む。Clはハロゲンであり、高い電気陰性度を持っている。この電気陰性度は結合から電子を引...")
- 08:49, 13 February 2024 Fire talk contribs created page spasticity (Q20907) (wbeditentity-create:2|en: spasticity, muscle paralysis, increased tendon reflex activity, hypertonia)
- 08:48, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/33/ja (Created page with "フロリジンは最初のタイプのグリフロジンで、SGLT2/SGLT1に対して非選択的であった。これはd-グルコースと芳香族ケトンからなる天然のO-アリール配糖体である。しかし、フロリジンは非常に不安定であり、小腸内のグルコシダーゼによって速やかに分解されるため、糖尿病治療のための経口投与医薬品としては使用できない。この不安定性...")
- 08:46, 13 February 2024 Fire talk contribs created page synucleinopathy (Q20906) (wbeditentity-create:2|en: synucleinopathy, neurodegenerative disease)
- 08:45, 13 February 2024 Fire talk contribs created page Parkinson's disease (Q20905) (wbeditentity-create:2|en: Parkinson's disease, long-term degenerative neurological disorder)
- 08:43, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/32/ja (Created page with "グリフロジンの合成には一般的に3つのステップがある。最初のステップはアリール置換基の構築であり、次のステップは糖へのアリール部分の導入またはアリール置換基のグルコシル化であり、最後のステップは糖のアリール化アノマー中心の脱保護と修飾である。")
- 08:41, 13 February 2024 Fire talk contribs created page psychiatric medication (Q20904) (wbeditentity-create:2|en: psychiatric medication, a drug used to treat mental health disorders)
- 08:41, 13 February 2024 Fire talk contribs created page mood stabilizer (Q20903) (wbeditentity-create:2|en: mood stabilizer, psychiatric medication used to treat mood disorders)
- 08:40, 13 February 2024 Fire talk contribs created page tranquilizer (Q20902) (wbeditentity-create:2|en: tranquilizer, drug that induces tranquility in an individual)
- 08:40, 13 February 2024 Fire talk contribs created page antipsychotics (Q20901) (wbeditentity-create:2|en: antipsychotics, class of medications)
- 08:38, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/31/ja (Created page with "最も一般的なグリフロジンはダパグリフロジン、エンパグリフロジン、カナグリフロジンである。構造の違いは比較的小さい。一般的な構造には、β位のアノマー炭素に芳香族基を持つグルコース糖が含まれる。グルコース糖部分とβ-異性体のアリール置換基に加えて、アリール基はジアリールメチレン構造から...")
- 08:37, 13 February 2024 Fire talk contribs created page neurotransmitter agent (Q20900) (wbeditentity-create:2|en: neurotransmitter agent, class of drugs used for their pharmacological action on any aspect of neurotransmitter systems; they include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function)
- 08:36, 13 February 2024 Fire talk contribs created page dopaminergic (Q20899) (wbeditentity-create:2|en: dopaminergic, drug that is used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons)
- 08:36, 13 February 2024 Fire talk contribs created page dopamine agonist (Q20898) (wbeditentity-create:2|en: dopamine agonist, drug that binds to and activates dopamine receptors)
- 08:35, 13 February 2024 Fire talk contribs created page Translations:SGLT2 inhibitor/30/ja (Created page with "== 構造活性相関 == {{Anchor|Structure-activity relationship}} グリフロジンの構造活性相関（SAR）は完全には解明されていない。")
